

Western Atrial Fibrillation 2018 Symposium Agenda

Friday, February 23, 2018

7:00 am Registration & Breakfast

7:35 am Welcome
Nassir Marrouche, MD

#ASKWAF2018 Kevin Campbell, MD; John Mandrola, MD

Session 1 Chairs: Melvin Scheinman, MD; Fred Han, MD

7:45 am Is AF ablation safer than AAD? A systematic review
John P. DiMarco, MD, PhD

8:00 am Interaction between hypercoagulability and atrial fibrillation
Ulrich Schotten, MD, PhD

8:15 am Clinical outcomes of AF mapping and rotor guided ablation
David Wilber, MD

8:30 am LAA closure: Long-term follow-up data
Rahul N. Doshi, MD

8:45 am Q&A

Session 2 Chairs: David Wilber, MD; Roger Freedman, MD

9:00 am It is all about lesion delivery: Is electroporation the future of AF ablation?
Pierre Jais, MD

9:15 am Atrial MR imaging: How to improve resolution?
Dana C. Peters, PhD

9:30 am How much AF is too much? (Especially with wearables everywhere...)
Mintu Turakhia, MD

9:45 am Is AF a marker or a risk for stroke?
Nazem Akoum, MD, MS

10:00 am Q&A

10:15 am Break

Session 3 Chairs: Jonathan Piccini, MD; Melvin Scheinman, MD

- 10:30 am Is AF ablation a first-line therapy in 2018?**
Eric Prystowsky, MD
- 10:45 am CABANA: What to expect?**
Douglas Packer, MD
- 11:00 am Esophageal protection during AF ablation**
Moussa C. Mansour, MD
- 11:15 am QoL post AF ablation: The CAPTAF trial**
Carina Blomström-Lundqvist, MD, PhD
- 11:30 am Q&A**
- 11:45 am Lunch**

Session 4 Chairs: Michael Cutler, DO, PhD; Fred Han, MD

- 12:30 pm Cryo-balloon for AF: Long-term results**
Bradley Knight, MD
- 12:45 pm Is it AF or the myopathy? Lessons from MR imaging**
Saman Nazarian, MD, PhD
- 1:00 pm Atrial fibrosis modeling: Clinical implications**
Natalia Trayanova, PhD
- 1:15 pm Mortality benefit post AF ablation: The CASTLE-AF trial**
Johannes Brachmann, MD
- 1:30 pm Q&A**

Session 5 Chairs: Jonathan Piccini, MD; Roger Freedman, MD

- 1:45 pm Do we still need to monitor for asymptomatic AF after ablation?**
Suneet Mittal, MD
- 2:00 pm Rotational activity and atrial fibrosis: How DECAAF II might help?**
Christian Sohns, MD
- 2:15 pm Post-ablation blanking period: 4, 8, 12 or zero weeks?**
David Callans, MD
- 2:30 pm Fibrosis and clinical AF: What are the DECAAFs teaching us?**
Nassir Marrouche, MD
- 2:45 pm Q&A**

3:00 pm	Break
Session 6	Chairs: David Callans, MD; Gaston R. Vergara, MD
3:15 pm	Targeting rotational activity during re-do procedures Sanjiv M. Narayan, MD, PhD
3:30 pm	Catheterized fiber-optics confocal microscopy for mapping of atrial fibrosis Frank B. Sachse, PhD
3:45 pm	Treatment of esophageal injury post AF ablation: A GI perspective Deborah Fisher, MD, MHS
4:00 pm	AF in heart failure patients: Lessons from SCD-HeFT Jeanne Poole, MD
4:15 pm	Q&A
Session 7	Moderators: Frank B. Sachse, PhD; Suneet Mittal, MD
4:30 pm	Atrial fibrosis in an experimental model: What have we learned? Stanley Nattel, MD
4:45 pm	When to anticoagulate AF patients with CHA₂DS₂-VASc <2? Andrea M. Russo, MD
5:00 pm	Are women at higher risk of AF? The Women's Health Study Christine Albert, MD, MPH
5:15 pm	Q&A
5:25 pm	Break
Session 8	Moderators: Walid Saliba, MD; Darryl S. Wells, MD
5:35 pm	Roundtable: How, when and why to monitor for AF—Examples from practice Ahmad Abdul-Karim, MD; Andres Bochoeyer, MD; Bengt Herweg, MD; Leenhapong Navaravong, MD; Kamran Rizvi, MD; Nischala Nannapaneni, MD; Bassam Wanna, MD; Marcos Daccarett, MD
6:30 pm	Adjourn

Saturday February 24, 2018

7:00 am **Registration & Breakfast**
Exhibits open

Session 9 **Chairs: John Mandrola, MD; Alexies Ramirez, MD**

7:30 am **Real world impact of NOACs: Neurologist perspective**
Scott Brehaut, MD

7:45 am **Debate: DOACs should be given for at least 6 months post-LAA implant**
Pro: Jonathan Lowy, MD
Con: Julian Chun, MD

8:00 am **ESC AF guidelines update**
Gerhard Hindricks, MD, PhD

8:15 am **LAA closure devices: Benefit beyond stroke prevention?**
Dhanunjaya Lakkireddy, MD

8:30 am **Q&A**

Session 10 **Chairs: Alexandru Costea, MD; Fred Han, MD**

8:45 am **Contemporary real-world and registry data of NOACs: Is Coumadin dead?**
Jonathan Hsu, MD, MAS

9:00 am **Low-voltage zone vs MR detected fibrosis: A comparison**
Takanori Yamaguchi, MD

9:15 am **Why we are struggling to agree on an ideal mapping system for AF?**
Olaf Dössel, PhD

9:30 am **Ablation of AF: 10 years of follow-up**
Andrea Natale, MD

9:45 am **Q&A**

10:00 am **Break**

Session 11 **Chairs: Prash Sanders, MBBS, PhD; Thomas J. McGarry, MD, PhD**

10:15 am **AF & OSA: Chicken and the egg**
Thomas F. Deering, MD, MBA

10:30 am **Cardiac fibrosis and treatment outcome: Lessons from CAMERA-MRI**
Jonathan M. Kalman, MBBS, PhD

- 10:45 am A Novel AF risk scoring model using MRI**
Brent D. Wilson, MD, PhD
- 11:00 am Ablation lesions post ablation: What have we learned from imaging?**
Mihail G. Chelu, MD, PhD
- 11:15 am Q&A**
- 11:30 am Lunch**

Session 12 Chairs: Thomas Deneke, MD; Nathan Segerson, MD

- 12:30 pm Real-time MRI for cardiac ablation**
Philipp Sommer, MD
- 12:45 pm How to modify lifestyle and educate the AF patient?**
Prash Sanders, MBBS, PhD
- 1:00 pm Role of atrial fibrosis during surgical AF ablation**
Ralph J. Damiano, Jr., MD
- 1:15 pm How to best monitor treatment with NOACs?**
Elaine M. Hylek, MD, MPH
- 1:30 pm Q&A**

Session 13 Chairs: Atul Verma, MD; Stephen Rechenmacher, MD

- 1:45 pm Real-time MRI cryo-balloon guided ablation**
Evgueni G. Kholmovski, PhD
- 2:00 pm Radiofrequency balloon systems**
Amin Al-Ahmad, MD
- 2:15 pm Approaches to ablate persistent AF in 2018: Why too many?**
Gregory Michaud, MD
- 2:30 pm Is transmural lesion an important endpoint during AF ablation? Show me the data!**
David Haines, MD
- 2:45 pm Q&A**
- 3:00 pm Break**

Session 14 Chairs: Christian Mahnkopf, MD; Alexandru Costea, MD

- 3:15 pm Patient-reported outcomes in AF**
Benjamin A. Steinberg, MD, MHS

3:30 pm	Off-label treatment of AF Kimberly A. Selzman, MD, MPH
3:45 pm	Importance of durable PVI for persistent AF Atul Verma, MD
4:00 pm	Q&A
Session 15	Chairs: Nassir Marrouche, MD; David Haines, MD
4:15 pm	Treatment of AF: Heart failure specialist's perspective Heribert Schunkert, MD
4:30 pm	4D flow in AF detected using MRI Christopher J. McGann, MD
4:45 pm	How early should we ablate AF? Temporal and structural criteria Oussama Wazni, MD
5:00 pm	Q&A
Session 16	Chairs: Kevin Campbell, MD; John Mandrolia, MD
5:15 pm	#ASKWAF2018: John D. Day, MD; Christian Mahnkopf, MD; Debbe McCall, MBA; Claudio Molito; Mellanie True Hills; Gaston R. Vergara, MD
6:30 pm	Adjourn